tiprankstipranks
Advertisement
Advertisement

ESPR Stock Latest News

Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts
RatingsEsperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts
16d ago
ESPR
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
PremiumCompany Announcements
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
27d ago
8K
ESPR
Esperion, Athyrium Capital enter $50M royalty financing agreement
PremiumThe Fly
Esperion, Athyrium Capital enter $50M royalty financing agreement
28d ago
ESPR
Esperion Therapeutics Earnings Call Signals Expansion
PremiumCompany Announcements
Esperion Therapeutics Earnings Call Signals Expansion
28d ago
ESPR
Esperion Therapeutics: CLEAR Outcomes Stroke Data and Commercial Momentum Underscore Buy-Rated Cardiovascular Franchise
PremiumRatings
Esperion Therapeutics: CLEAR Outcomes Stroke Data and Commercial Momentum Underscore Buy-Rated Cardiovascular Franchise
30d ago
ESPR
Esperion showcases new data from CLEAR Outcomes trial
PremiumThe FlyEsperion showcases new data from CLEAR Outcomes trial
1M ago
ESPR
Esperion management to meet with Piper Sandler
Premium
The Fly
Esperion management to meet with Piper Sandler
1M ago
ESPR
Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline
Premium
The Fly
Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline
1M ago
ESPR
Esperion price target raised to $5 from $4 at Citizens
PremiumThe Fly
Esperion price target raised to $5 from $4 at Citizens
2M ago
ESPR
Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks
PremiumCompany Announcements
Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks
2M ago
ESPR
Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating
PremiumRatings
Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating
2M ago
ESPR
Options Volatility and Implied Earnings Moves Today, March 10, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 10, 2026
2M ago
FNV
KSS
Esperion reports Q4 EPS 22c, consensus 28c
PremiumThe FlyEsperion reports Q4 EPS 22c, consensus 28c
2M ago
ESPR
Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025
Premium
The Fly
Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025
2M ago
ESPR
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
Premium
Ratings
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
2M ago
ESPR
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio
PremiumCompany Announcements
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio
2M ago
8K
ESPR
Esperion signs definitive acquisition of Corstasis Therapeutics
PremiumThe Fly
Esperion signs definitive acquisition of Corstasis Therapeutics
2M ago
ESPR
ESPR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESPR Earnings this Week: How Will it Perform?
2M ago
ESPR
Esperion Therapeutics: Strengthened Bempedoic Acid Patent Protection and Growing Cardiovascular Franchise Support Buy Rating
PremiumRatings
Esperion Therapeutics: Strengthened Bempedoic Acid Patent Protection and Growing Cardiovascular Franchise Support Buy Rating
2M ago
ESPR
Esperion reaches settlement agreement with Alkem
PremiumThe FlyEsperion reaches settlement agreement with Alkem
2M ago
ESPR
Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M
Premium
The Fly
Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M
4M ago
ESPR
Esperion (ESPR): Growing Global Guideline Endorsements and Regulatory Milestones for Bempedoic Acid Support Buy Rating and $16 Target
Premium
Ratings
Esperion (ESPR): Growing Global Guideline Endorsements and Regulatory Milestones for Bempedoic Acid Support Buy Rating and $16 Target
4M ago
ESPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >